Clindex by EvidentIQ Group Launches Revolutionary Site Feasibility Feature to Transform Clinical Trial Management
Transform Site Feasibility Assessments into a Fully Digital, Streamlined Process
(PresseBox) - EvidentIQ Group GmbH announced today the launch of an innovative Site Feasibility feature within Clindex, one of its Electronic Data Capture (EDC) systems. This transformative addition to the Clindex eClinical platform introduces a comprehensive solution to streamline clinical trial site selection and management, addressing one of the industry's most persistent challenges: the time-consuming and complex process of clinical trial feasibility assessment.
The new feature digitizes and centralizes the entire site feasibility process, replacing traditional paper-based workflows with an integrated digital platform. This advancement enables sponsors to distribute study information, collect site responses, and evaluate site suitability within a single, unified system.
"Clinical trial site selection has historically been a major bottleneck in trial initiation, often leading to delays and increased costs," said Jill Tufano, President at EvidentIQ, LLC . "Our new Site Feasibility feature revolutionizes this process, offering a digital solution that significantly reduces administrative burden while improving decision-making quality."
Key features of the Clindex Site Feasibility solution include:
Digital feasibility questionnaires that eliminate paper-based processes
Comprehensive sponsor evaluation and site selection tools
Seamless workflow integration from feasibility to site activation
Centralized site database for future study reference
Complete audit trail ensuring regulatory compliance
The platform maintains the highest standards of data security and regulatory compliance, including GCP and GDPR requirements, through encrypted data storage and role-based access controls. Its scalable architecture supports trials of any size, from single-site studies to complex multi-center trials.
"We've built this feature with both sponsors and sites in mind," added Philip Jorgensen,Senior Director, R&D Clindex. "The integration with our existing EDC, CTMS, and eTMF functionalities creates a seamless experience that saves time, reduces errors, and ultimately accelerates the path to trial initiation."
The Clindex Site Feasibility feature is available immediately as part of the Clindex eClinical platform. For more information about the feature and its capabilities, please visit www.clindex.com or contact jill.tufano(at)evidentiq.com
EvidentIQ is a leading provider of innovative eClinical solutions, offering advanced technology for clinical trials and data management. As a global company, EvidentIQ specializes in Electronic Data Capture (EDC) systems, catering to diverse research needs with three powerful platforms: Marvin EDC (Germany), Dacima Software (Canada), and Clindex (USA). With a strong commitment to efficiency, compliance, and data integrity, EvidentIQ empowers pharmaceutical, biotech, and medical research organizations worldwide. By combining expertise in software development with deep industry knowledge, EvidentIQ delivers cutting-edge solutions that streamline clinical trial processes and enhance decision-making.
Unternehmensinformation / Kurzprofil:
EvidentIQ is a leading provider of innovative eClinical solutions, offering advanced technology for clinical trials and data management. As a global company, EvidentIQ specializes in Electronic Data Capture (EDC) systems, catering to diverse research needs with three powerful platforms: Marvin EDC (Germany), Dacima Software (Canada), and Clindex (USA). With a strong commitment to efficiency, compliance, and data integrity, EvidentIQ empowers pharmaceutical, biotech, and medical research organizations worldwide. By combining expertise in software development with deep industry knowledge, EvidentIQ delivers cutting-edge solutions that streamline clinical trial processes and enhance decision-making.
Datum: 23.06.2025 - 14:27 Uhr
Sprache: Deutsch
News-ID 723383
Anzahl Zeichen: 3456
contact information:
Contact person: Sabine Birkner
Town:
Hamburg
Phone: +49 (89) 4522775-250
Kategorie:
Manufacturing & Production
Diese Pressemitteilung wurde bisher 191 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clindex by EvidentIQ Group Launches Revolutionary Site Feasibility Feature to Transform Clinical Trial Management"
steht unter der journalistisch-redaktionellen Verantwortung von
EvidentIQ Group GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
